AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 31 min read$VIVS

VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity

VivoSim Labs (VIVS) is developing a rat liver model to complement its human liver model, aiming to improve drug toxicity predictions. This could help pharma companies make earlier decisions on drug candidates, potentially expanding VIVS's NAMkind(TM) platform's use. The FDA's push for human-relevant testing may provide a favorable backdrop. VIVS expects 500%+ fiscal 2027 revenue growth from its NAM-based business.

Original reporting
marketscreener.com
Published Sep 3, 2026, 8:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$VIVS
Neutral
medium confidence
Mentioned
$VIVS
Relevance
5/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$VIVSNeutralLow
01

Why it matters

The new rat model could broaden the utility of its NAMkind™ platform, potentially increasing contract research revenue.

02

Market read

Adds a new capability to an existing preclinical testing platform, modestly relevant for biotech investors.

03

What to watch

Regulatory endorsement and competitive landscape of other NAM providers.

Relevance 5/10Novelty 5/10Timing: none

Background

VivoSim Labs (NASDAQ: VIVS) focuses on 3D human tissue models and AI‑driven toxicology predictions.

Company-level read

Ticker impact

$VIVSNeutralMedium confidence
Context

VivoSim Labs announced a new cross-species toxicology platform expanding its NAMkind™ offering.

Expected impact

Modest upside if platform gains early adopters.

Evidence & confidence

The announcement is a forward‑looking development without immediate revenue numbers; impact depends on commercial uptake.

Market effects

Sector

Highlights growing interest in non‑animal testing methods within pharma R&D.

Regional

U.S. biotech sector may see incremental interest.

Global

Limited to companies pursuing NAM approaches.

Counterpoint

What could challenge this read

Without concrete contracts or revenue, the platform may struggle to gain traction.

Key entities

  • Company
    VivoSim Labs

    Developer of human tissue models and predictive toxicology tools.

Read at source← All news

Related articles

OCT 7
$VIVSMed

FDA updates regulations to allow non-animal drug safety testing

The FDA updated regulations to allow non-animal methods for drug safety testing, replacing 'animal tests' with 'nonclinical tests'. VivoSim Labs (VIVS) offers 3D human cellular models for preclinical testing, aiming to reduce drug development costs by identifying toxic molecules early. The company's models use primary human cells and could help avoid costly failures in clinical trials.

investing.com2 min
OCT 7
$VIVSMed

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

VivoSim Labs (VIVS) welcomes FDA's updated regulations allowing greater use of non-animal testing methods. The rule replaces 'animal tests' with 'nonclinical tests,' benefiting VivoSim's 3D human cellular models. VivoSim's models can identify drug safety risks earlier, reducing development costs. The company expects accelerated adoption of its NAM models following the FDA's roadmap.

globenewswire.com2 min
AUG 6
$VIVSMedAI 8/10

VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 – Minichart

VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.

minichart.com.sg5 min
AUG 6
$VIVSMed

VivoSim Provides Financial and Listing Compliance Update

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VivoSim Provides Financial and Listing Compliance Update San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, t

SEC EDGAR 8-K2 min
AUG 6
$VIVSMed

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.

stocktitan.net4 min